Literature DB >> 17562435

Forty years experience of treating cancer of unknown primary.

Nicholas Pavlidis1.   

Abstract

Cancer of unknown primary site (CUP) is not a rare tumour. It accounts as the seventh to eighth most frequently diagnosed cancer in a general medical oncology service. Since CUP is not a homogeneous disease and it consists of different favourable and unfavourable sub-sets, treatment of each clinicopathological entity requires a unique approach. The spectrum of therapeutic management includes both locoregional and systemic therapy and should intend to offer optimal benefit to favourable CUP patients and palliative care to unfavourable cases. This review article provides both a historical outline of CUP treatment as well as a helpful therapeutic guide to every oncologist who treats CUP patients.

Entities:  

Mesh:

Year:  2007        PMID: 17562435     DOI: 10.1080/02841860701243095

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  17 in total

Review 1.  Progress in refining the clinical management of cancer of unknown primary in the molecular era.

Authors:  Elie Rassy; Nicholas Pavlidis
Journal:  Nat Rev Clin Oncol       Date:  2020-04-29       Impact factor: 66.675

2.  CUP Syndrome in Neuroendocrine Neoplasia: Analysis of Risk Factors and Impact of Surgical Intervention.

Authors:  Nehara Begum; Ulrich Wellner; Christoph Thorns; Georg Brabant; Martin Hoffmann; Conny Georg Bürk; Hendrik Lehnert; Tobias Keck
Journal:  World J Surg       Date:  2015-06       Impact factor: 3.352

3.  Phase II trials in patients with carcinoma of unknown primary: a pooled data analysis.

Authors:  Antoine Adenis; Charles Ferté; Nicolas Penel
Journal:  Invest New Drugs       Date:  2009-05-08       Impact factor: 3.850

4.  [Radiological diagnostics in CUP syndrome].

Authors:  P M Kazmierczak; K Nikolaou; A Rominger; A Graser; M F Reiser; C C Cyran
Journal:  Radiologe       Date:  2014-02       Impact factor: 0.635

5.  A case of long-term recurrence-free poorly differentiated neuroendocrine carcinoma of lymph nodes treated by surgical resection without any chemotherapy.

Authors:  Shigeo Hisamori; Hiroshi Okabe; Akihiko Yoshizawa; Yoshiharu Sakai
Journal:  Int J Clin Oncol       Date:  2010-03-12       Impact factor: 3.402

6.  Clinical presentation of carcinoma of unknown primary: 14 years of experience.

Authors:  Jun Ho Yi; Yoon La Choi; Su Jin Lee; Hee Kyung Ahn; Kyung Kee Baek; Taekyu Lim; Duk Joo Lee; Bo Ram Han; Ha Yeon Lee; Hyun Jung Jun; Jeeyun Lee; Yeon Hee Park
Journal:  Tumour Biol       Date:  2010-08-10

7.  Unfavorable cancers of unknown primaries: presentation and prognostic factors. A population-based 8-year experience.

Authors:  Margareta Randén; Maria Helde-Frankling; Sara Runesdotter; Peter Gunvén
Journal:  Med Oncol       Date:  2013-09-18       Impact factor: 3.064

8.  Undifferentiated pelvic adenocarcinomas: diagnostic potential of protein profiling and multivariate analysis.

Authors:  U J Roblick; F G Bader; C Lenander; U Hellman; K Zimmermann; S Becker; A Ost; A Alaiya; H-P Bruch; R Keller; L Mirow; B Franzén; T Ried; G Auer; J K Habermann
Journal:  Int J Colorectal Dis       Date:  2008-02-22       Impact factor: 2.571

9.  Predictive value of seven preoperative prognostic scoring systems for spinal metastases.

Authors:  Andreas Leithner; Roman Radl; Gerald Gruber; Markus Hochegger; Katharina Leithner; Heike Welkerling; Peter Rehak; Reinhard Windhager
Journal:  Eur Spine J       Date:  2008-09-12       Impact factor: 3.134

10.  Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis.

Authors:  Thomas C Kwee; Robert M Kwee
Journal:  Eur Radiol       Date:  2008-10-17       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.